GoodRx Holdings, Inc. recently reported fourth-quarter 2025 revenue of US$194.79 million and full-year revenue of US$796.85 million, alongside the launch of GoodRx Employer Direct to help employers ...

On Feb. 5, the Trump administration launched TrumpRx, a new digital platform designed to help Americans navigate the often-crushing costs of prescription drugs. While President Trump has called the ...

TrumpRx is primarily for people who pay for their prescriptions out-of-pocket. There may be cheaper generic options at direct ...

GoodRx (NASDAQ:GDRX) executives said the company ended 2025 with what it called “disciplined execution” across strategic ...

GoodRx projects Pharma Direct revenue to grow at least 30% year-over-year in 2026. Management anticipates continued acceleration in condition-specific subscriptions launched in late 2025, with weight ...

GoodRx Holdings, Inc. ( GDRX) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2025 Earnings ...

The Trump administration's new website, TrumpRx, is a poor imitation of GoodRx with fewer options, and does not provide real relief for families struggling with high drug prices.

In the case of brand-name Crestor (rosuvastatin), the average retail price is close to $400 for one month, while a three-month supply at a national pharmacy is $780. For generic rosuvastatin (which ...

The Trump administration’s new website, TrumpRx, is a poor imitation of GoodRx with fewer options, and does not provide real ...

Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance Pharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025SANTA ...

Drug pricing 2026 forces are reshaping pharmacy economics through Medicare negotiations, FTC actions, and federal pricing models.

President Trump touted his efforts to lower prescription drug costs during his State of the Union address Tuesday, and ...